Related references
Note: Only part of the references are listed.Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara
Alejandro Marin-Lopez et al.
VACCINE (2020)
Vector competence is strongly affected by a small deletion or point mutations in bluetongue virus
Rene G. P. van Gennip et al.
PARASITES & VECTORS (2019)
Prospects of Next-Generation Vaccines for Bluetongue
Piet A. van Rijn
FRONTIERS IN VETERINARY SCIENCE (2019)
Lesions and Cellular Tropism of Natural Rift Valley Fever Virus Infection in Adult Sheep
Lieza Odendaal et al.
VETERINARY PATHOLOGY (2019)
Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor
Alejandro Marin-Lopez et al.
VIRUSES-BASEL (2019)
CD8 T Cell Responses to an Immunodominant Epitope within the Nonstructural Protein NS1 Provide Wide Immunoprotection against Bluetongue Virus in IFNAR-/- Mice
Alejandro Marin-Lopez et al.
JOURNAL OF VIROLOGY (2018)
Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination
Gema Lorenzo et al.
VETERINARY RESEARCH (2018)
Current and next-generation bluetongue vaccines: Requirements, strategies, and prospects for different field situations
Femke Feenstra et al.
CRITICAL REVIEWS IN MICROBIOLOGY (2017)
Rift Valley fever virus: strategies for maintenance, survival and vertical transmission in mosquitoes
Sarah Lumley et al.
JOURNAL OF GENERAL VIROLOGY (2017)
Rift Valley Fever
Amy Hartman
CLINICS IN LABORATORY MEDICINE (2017)
Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(-/-) mice conferring protection against serotypes 1 and 4 of bluetongue virus
Alejandro Marin-Lopez et al.
ANTIVIRAL RESEARCH (2017)
Development of plant-produced protein body vaccine candidates for bluetongue virus
Albertha R. van Zyl et al.
BMC BIOTECHNOLOGY (2017)
Pathological Characterization Of IFNAR(-/-) Mice Infected With Bluetongue Virus Serotype 4
Alejandro Marin-Lopez et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2016)
Development of a sheep challenge model for Rift Valley fever
Bonto Faburay et al.
VIROLOGY (2016)
Non-structural protein NS3/NS3a is required for propagation of bluetongue virus in Culicoides sonorensis
Femke Feenstra et al.
PARASITES & VECTORS (2015)
An experimental subunit vaccine based on Bluetongue virus 4 VP2 protein fused to an antigen-presenting cells single chain antibody elicits cellular and humoral immune responses in cattle, guinea pigs and IFNAR(-/-) mice
D. M. Legisa et al.
VACCINE (2015)
Application of Bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2
Femke Feenstra et al.
VACCINE (2015)
Rift Valley fever virus: A review of diagnosis and vaccination, and implications for emergence in Europe
Karen L. Mansfield et al.
VACCINE (2015)
VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) mice
Alejandro Marin-Lopez et al.
ANTIVIRAL RESEARCH (2014)
Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge
Femke Feenstra et al.
JOURNAL OF GENERAL VIROLOGY (2014)
A Novel Poxvirus-Based Vaccine, MVA-CHIKV, Is Highly Immunogenic and Protects Mice against Chikungunya Infection
Juan Garcia-Arriaza et al.
JOURNAL OF VIROLOGY (2014)
Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle
Jenna Anderson et al.
VACCINE (2014)
Novel Bluetongue Virus in Goats, Corsica, France, 2014
Stephan Zientara et al.
EMERGING INFECTIOUS DISEASES (2014)
Ovine and murine T cell epitopes from the non-structural protein 1 (NS1) of bluetongue virus serotype 8 (BTV-8) are shared among viral serotypes
Jose M. Rojas et al.
VETERINARY RESEARCH (2014)
Protection of IFNAR (-/-) Mice against Bluetongue Virus Serotype 8, by Heterologous (DNA/rMVA) and Homologous (rMVA/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2
Tamara Kusay Jabbar et al.
PLOS ONE (2013)
Clinical development of Modified Vaccinia virus Ankara vaccines
Sarah C. Gilbert
VACCINE (2013)
Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice
George M. Warimwe et al.
VIROLOGY JOURNAL (2013)
A Single Immunization with MVA Expressing GnGc Glycoproteins Promotes Epitope-specific CD8+-T Cell Activation and Protects Immune-competent Mice against a Lethal RVFV Infection
Elena Lopez-Gil et al.
PLOS NEGLECTED TROPICAL DISEASES (2013)
Multiserotype Protection Elicited by a Combinatorial Prime-Boost Vaccination Strategy against Bluetongue Virus
Eva Calvo-Pinilla et al.
PLOS ONE (2012)
Bluetongue virus non-structural protein 1 is a positive regulator of viral protein synthesis
Mark Boyce et al.
VIROLOGY JOURNAL (2012)
Generation of Replication-Defective Virus-Based Vaccines That Confer Full Protection in Sheep against Virulent Bluetongue Virus Challenge
Eiko Matsuo et al.
JOURNAL OF VIROLOGY (2011)
Immunization of knock-out α/β interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen
Valentina Franceschi et al.
VACCINE (2011)
A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR-/- mice upon lethal virus challenge
Hani Boshra et al.
VACCINE (2011)
Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass
Robert Alcock et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR-/- mice induced by different DNA vaccination regimens
Gema Lorenzo et al.
VACCINE (2010)
The Pathology and Pathogenesis of Bluetongue
N. J. Maclachlan et al.
JOURNAL OF COMPARATIVE PATHOLOGY (2009)
Establishment of a Bluetongue Virus Infection Model in Mice that Are Deficient in the Alpha/Beta Interferon Receptor
Eva Calvo-Pinilla et al.
PLOS ONE (2009)
Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection
Eva Calvo-Pinilla et al.
VACCINE (2009)
Vaccines against bluetongue in Europe
Giovanni Savini et al.
COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES (2008)
Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep
Gerna Lorenzo et al.
VACCINE (2008)
Potential Vectors of Rift Valley Fever Virus in the Mediterranean Region
Sara Moutailler et al.
VECTOR-BORNE AND ZOONOTIC DISEASES (2008)
Recombinant capripoxviruses expressing proteins of bluetongue virus:: Evaluation of immune responses and protection in small ruminants
Aurelie Perrin et al.
VACCINE (2007)
Bluetongue virus detection by two real-time RT-qPCRs targeting two different genomic segments
J. F. Toussaint et al.
JOURNAL OF VIROLOGICAL METHODS (2007)
Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep
Josh D. Boone et al.
VACCINE (2007)
Rift Valley fever virus
R Flick et al.
CURRENT MOLECULAR MEDICINE (2005)
Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker
JM Sánchez-Puig et al.
BIOTECHNIQUES (2005)
Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
I Drexler et al.
CURRENT OPINION IN BIOTECHNOLOGY (2004)
Rift Valley fever epidemic in Saudi Arabia: Epidemiological, clinical, and laboratory characteristics
TA Madani et al.
CLINICAL INFECTIOUS DISEASES (2003)
Sensitive and viable identification of antigen-specific CD8+T cells by a flow cytometric assay for degranulation
MR Betts et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2003)
Rift Valley fever: an uninvited zoonosis in the Arabian peninsula
HH Balkhy et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2003)
Share Paper
